Abstract
A new dihydropyranexanthone derived from the natural xanthone lichexanthone (1) was synthesised and, together with other 18 derivatives including ω-bromo and ω-aminoalkoxylxanthones (containing methyl, ethyl, propyl, tertbutylamino and piperidinyl moieties), were tested against Mycobacterium tuberculosis. Nine ω-aminoalkoxylxanthones showed good antimycobacterial activity, and their in vitro cytotoxicity was determined using VERO cells in order to calculate the selectivity index (SI). One of these nitrogenated xanthone derivatives showed very promising results, with MIC of 2.6 μM and SI of 48. This MIC is comparable to values found in “first and second line” drugs commonly used to treat TB. In order to understand better about this compound, it was evaluated together with two other ones that showed good SI, against resistant clinical strains of M. tuberculosis to verify the existence of cross-resistance. A chemometrical approach was useful to establish a pattern of antitubercular activity among the group of ω-aminoalkoxylxanthones, according to some structural and chemical features.
Keywords: Chemometrics, lichen, structural modifications, tuberculosis, xanthone.
Medicinal Chemistry
Title:Increment of Antimycobaterial Activity on Lichexanthone Derivatives
Volume: 9 Issue: 7
Author(s): Ana Camila Micheletti, Neli Kika Honda, Fernando R. Pavan, Clarice Q. F. Leite, Maria de Fatima Cepa Matos, Renata Trentin Perdomo, Danielle Bogo, Glaucia Braz Alcantara and Adilson Beatriz
Affiliation:
Keywords: Chemometrics, lichen, structural modifications, tuberculosis, xanthone.
Abstract: A new dihydropyranexanthone derived from the natural xanthone lichexanthone (1) was synthesised and, together with other 18 derivatives including ω-bromo and ω-aminoalkoxylxanthones (containing methyl, ethyl, propyl, tertbutylamino and piperidinyl moieties), were tested against Mycobacterium tuberculosis. Nine ω-aminoalkoxylxanthones showed good antimycobacterial activity, and their in vitro cytotoxicity was determined using VERO cells in order to calculate the selectivity index (SI). One of these nitrogenated xanthone derivatives showed very promising results, with MIC of 2.6 μM and SI of 48. This MIC is comparable to values found in “first and second line” drugs commonly used to treat TB. In order to understand better about this compound, it was evaluated together with two other ones that showed good SI, against resistant clinical strains of M. tuberculosis to verify the existence of cross-resistance. A chemometrical approach was useful to establish a pattern of antitubercular activity among the group of ω-aminoalkoxylxanthones, according to some structural and chemical features.
Export Options
About this article
Cite this article as:
Micheletti Camila Ana, Honda Kika Neli, Pavan R. Fernando, Leite Q. F. Clarice, Matos de Fatima Cepa Maria, Perdomo Trentin Renata, Bogo Danielle, Alcantara Braz Glaucia and Beatriz Adilson, Increment of Antimycobaterial Activity on Lichexanthone Derivatives, Medicinal Chemistry 2013; 9 (7) . https://dx.doi.org/10.2174/1573406411309070003
DOI https://dx.doi.org/10.2174/1573406411309070003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanistic Approach to Explore Isoniazid Derivatives as Antitubercular Agents Using KNN-MF Based-QSAR Analysis, Pharmacophore Modeling and Molecular Docking
Current Drug Therapy Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tuberculosis and its Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Terpenoids form the Sea: Chemical Diversity and Bioactivity
Current Organic Chemistry Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets Archaeosome Immunostimulatory Vaccine Delivery System
Current Drug Delivery Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Application of Poloxamers for the Development of Drug Delivery System to Treat Leishmaniasis: A Review
Current Drug Targets Predicting Antimicrobial Drugs and Targets with the MARCH-INSIDE Approach
Current Topics in Medicinal Chemistry New Aminoacyl-tRNA Synthetase Inhibitors as Antibacterial Agents
Current Drug Targets - Infectious Disorders Structural Genomics and Drug Discovery for Infectious Diseases
Infectious Disorders - Drug Targets Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Therapeutic Approaches Blocking Glycan Synthesis as Targeting Strategy for Malaria
Current Clinical Pharmacology Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Novel Thiazole Carboxylic Acid Derivatives Possessing a “Zinc Binding Feature” as Potential Human Glyoxalase-I Inhibitors
Letters in Drug Design & Discovery Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study
Current HIV Research CCR2 Antagonists
Current Topics in Medicinal Chemistry Prevention of Microbial Communities: Novel Approaches Based Natural Products
Current Pharmaceutical Biotechnology The Role of IL-15 Signaling in the Induction of Innate Antiviral Responses
Current Signal Transduction Therapy Patent Selections
Recent Patents on Biotechnology